trending Market Intelligence /marketintelligence/en/news-insights/trending/PEnqFTItT0ka552D8Wkxgw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA approves new generic blood pressure drug to address ongoing shortage

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA approves new generic blood pressure drug to address ongoing shortage

The U.S. Food and Drug Administration approved Alkem Laboratories Ltd.'s new generic version of common blood pressure and heart failure drug valsartan, in an attempt to relieve shortages stemming from mass recalls of the medicine.

According to the FDA's March 12 press release, the agency prioritized Alkem's generic-drug review and ensured that the India-based pharmaceutical company's manufacturing process did not result in cancer-causing nitrosamine impurities containing N-nitrosodimethylamine, or NDMA, and N-nitrosodiethylamine, or NDEA.

The carcinogenic impurities had been found in batches of valsartan medications from Mylan NV and Teva Pharmaceutical Industries Ltd.

The ongoing recalls in the U.S. and Europe, which first began in July 2018, now also include losartan and irbesartan products. Valsartan, losartan and irbesartan are angiotensin II receptor blockers, or ARBs.

The FDA said it will continue to work with drug manufacturers to evaluate and expedite ARB drug applications that address the shortage, as well as provide additional supplies of anti-hypertensive medicines.

In the meantime, the FDA's list of recalled products will be updated accordingly as the investigation into ARB drugs continues.